Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 20, 2024. 

NeurologyLive® Friday 5 — December 20, 2024

Managing ALS, particularly its respiratory complications, requires a collaborative multidisciplinary team—including neurologists, pulmonologists, and respiratory therapists—working together to address the complexities of respiratory failure, the leading cause of death in these patients.

Breathing Life Into ALS Care: The Vital Role of Multidisciplinary Teams

Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.

Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes

Videos

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

Assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona

, has been with the team since September 2022. Follow her on Twitter 

The program assembles a collaborative team of in-house and external experts in research, clinical care, and regulatory affairs to navigate gene therapy programs through the drug development process.

FDA Grants MDA Kickstart Program Rare Pediatric Disease Designation and Orphan Drug Designation in Congenital Myasthenic Syndrome

IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

IJMSC Insights: Blanca De Dios Perez on Employment and Multiple Sclerosis

Pediatric epilepsy specialist at University of California, San Francisco.

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

Advancing Epilepsy Research Through Implementation Science and Biomarkers: Adam Numis, MD; Laura Kirkpatrick, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

AES 2024

CTAD 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy

In this program, sleep experts will discuss the importance of timely and accurate diagnosis, recent approvals and available treatment options for the management of narcolepsy and excessive daytime sleepiness.

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

Narcolepsy  Overview 

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Burden and Risk Factor of Narcolepsy

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Diagnosis of Narcolepsy

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

EDS Evaluation 

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

Available Resources for Narcolepsy Treatment

Neurology experts describe the goals of therapy for narcolepsy treatment. 

Goals of Therapy for Narcolepsy 

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

Pharmacological Treatment Options for Narcolepsy

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options. 

EDS and Narcolepsy Treatment Options

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

Pitolisant: Mechanism of Action

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Pitolisant Efficacy and Safety

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Solriamfetol Efficacy and Safety

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy 

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences. 

Unmet Needs in Narcolepsy and Clinical Pearls

Peer Exchange

Clinical

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy

EP: 1.Narcolepsy Overview

EP: 2.Burden and Risk Factor of Narcolepsy

EP: 3.Diagnosis of Narcolepsy

EP: 4.EDS Evaluation

EP: 5.Available Resources for Narcolepsy Treatment

EP: 6.Goals of Therapy for Narcolepsy

EP: 7.Pharmacological Treatment Options for Narcolepsy

EP: 8.EDS and Narcolepsy Treatment Options

EP: 9.Pitolisant: Mechanism of Action

EP: 10.Pitolisant Efficacy and Safety

EP: 11.Solriamfetol Efficacy and Safety

EP: 12.Sodium Oxybate and Antidepressants for Treatment of Cataplexy

EP: 13.Unmet Needs in Narcolepsy and Clinical Pearls